• Daniela Pugliese, Marco Daperno, Gionata Fiorino, Edoardo Savarino, Elena Mosso, Livia Biancone, Anna Testa, Lucio Sarpi, Maria Cappello, Giorgia Bodini, Flavio Caprioli, Stefano Festa, Gabriella Laino, Giovanni Maconi, Silvia Mazzuoli, Giammarco Mocci, Alessandro Sartini, Alessandra D'Amore, Stefano Alivernini, Elisa Gremese, and Alessandro Armuzzi.
• IBD Unit, Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
• Dig Liver Dis. 2019 Jul 1; 51 (7): 972-977.

BackgroundFew data exist regarding the effectiveness of ustekinumab in inflammatory bowel disease (IBD) patients treated for concomitant psoriasis or psoriatic arthritis.Aimsto describe the outcomes of IBD patients who received subcutaneous ustekinumab through a dermatological or rheumatological prescription.MethodsThis multicenter, retrospective study included all IBD patients who were started on ustekinumab for concomitant active psoriasis/ psoriatic arthritis, irrespective of IBD activity. The primary endpoint was overall ustekinumab persistence, defined as the maintenance of therapy because of sustained clinical benefit for IBD.ResultsSeventy patients (64 Crohn's disease / 6 ulcerative colitis) were enrolled. The median follow-up on ustekinumab therapy was 10.7 months (range, 1.4-67.3). Twelve patients (17.1%) withdrew the treatment after a median of 7.4 months (range, 0.9-23.8). The cumulative probability of maintaining ustekinumab treatment was 97.1% at 6 months and 77.1% at 12 months. Among the 56 patients with baseline active IBD, 34 (60.7%) were in clinical remission at the last follow-up visit. Their cumulative probability of achieving clinical remission was 84.7% and 63.9% at 6 and 12 months, respectively. Two patients stopped ustekinumab for an adverse event.ConclusionsSubcutaneous ustekinumab had a good effectiveness profile for IBD patients treated for concomitant dermatological or rheumatological conditions.Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

29 keywords...

hide…